---
title: "Baxter Int'l Q2 Profit Rises; Boosts FY26 Outlook; Stock Surges 15%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294358249.md"
description: "Baxter International reported Q2 net income of $126 million, up from $91 million year-over-year. Worldwide net sales grew 5% to $2.96 billion. The company boosted its FY26 outlook, projecting adjusted earnings of $1.95-$2.15 per share and 3-4% reported sales growth. Following the positive results and upgraded guidance, Baxter's stock surged over 15% in pre-market trading."
datetime: "2026-07-30T11:43:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294358249.md)
  - [en](https://longbridge.com/en/news/294358249.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294358249.md)
generator: "portal-rs"
---

# Baxter Int'l Q2 Profit Rises; Boosts FY26 Outlook; Stock Surges 15%

Add  as your preferred news source on Google

 Add Now

Health care company Baxter International, Inc. (BAX) reported Thursday net income attributable to shareholders for the second quarter of $126 million or $0.24 per share, up from $91 million or $0.18 per share in the prior-year quarter.

Excluding items, adjusted income from continuing operations for the quarter was $0.56 per share, compared to $0.59 per share last year.

Worldwide net sales for the quarter grew 5 percent to $2.96 billion from $2.81 billion in the same quarter last year. It also grew 5 percent on an organic basis.

Continuing operations exclude Baxter's Kidney Care business, which was divested in January 2025, and is reported as discontinued operations.

Looking ahead to fiscal 2026, the company now projects adjusted earnings from continuing operations in a range of $1.95 to $2.15 per share on sales growth from continuing operations of 3 to 4 percent on a reported basis, with 2 to 3 percent organic sales growth from continuing operations.

Previously, the company expected adjusted earnings from continuing operations in a range of $1.85 to $2.05 per share on sales growth from continuing operations of flat to 1 percent on a reported basis, with flat organic sales growth from continuing operations.

In Thursday's pre-market trading, BAX is trading on the NYSE at $28.50, up $3.74 or 15.11 percent.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [BAX.US](https://longbridge.com/en/quote/BAX.US.md)

## Related News & Research

- [How Baxter’s Finance Leadership Overhaul and Debt Moves Will Impact Baxter International (BAX) Investors](https://longbridge.com/en/news/296816915.md)
- [Front Street Capital Management Inc. Buys Shares of 1,319,992 Baxter International Inc. $BAX](https://longbridge.com/en/news/296881556.md)
- [XORTX discloses US$240,000 finder’s fees tied to Vectus renal program acquisition after omission](https://longbridge.com/en/news/297312983.md)
- [04:21 ETNew Real-World Data Show penKid Adding Decision Support for Kidney Replacement Therapy in Critical Care](https://longbridge.com/en/news/297147475.md)
- [NewEdge Wealth LLC Acquires Shares of 43,244 Baxter International Inc. $BAX](https://longbridge.com/en/news/296678489.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**